The participation of CD40L in pro-inflammatory and autoimmune disease, such as arthritis, nephritis, organ rejection, autoimmune diabetes, inflammatory bowel disease, and SLE (28–32) has led to the clinical evaluation of antibody-mediated neutralization of CD40L in human disease. This evidence concerns the gene CD40LG and autoimmune disease.